Innate Immunotherapeutics Limited is a medical biotechnology company with offices in Sydney and Auckland.
The Company is currently conducting a Phase 2B efficacy trial of its drug candidate (MIS416) in patients with secondary progressive multiple sclerosis (SPMS). There are currently no safe and effective ongoing treatments for this progressive and highly disabling form of multiple sclerosis.
On completion of this study, expected 2017, the Company’s strategy is to partner this clinical programme application with ‘big pharma’ to complete approval trials and launch sales into the worldwide unmet market for SPMS.
The Board of Innate Immunotherapeutics Limited (ASX:IIL) (“Innate”) has resolved to make a private placement (“Placement”) to raise gross proceeds of A$2,000,000.
Innate Immunotherapeutics Limited (ASX Code: IIL), together with a number of Australian, Canadian, and Danish scientific collaborators, has had multiple abstracts accepted for presentation at the Amer…